This supplementary has been provided by the authors to give readers additional information about their work.
Supplementary material for Pharmacological interventions for prevention and management of delirium in intensive care patients: a systematic overview of reviews and meta-analyses Table 1 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
102-104

METHODS
Protocol and registration 5
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
108-109
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
114-145
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
147-152, Electronic supplementary
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. Electronic supplementary Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the metaanalysis).
155-164
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
165-167
4
Data items 11
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
169-180
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 2 ) for each metaanalysis.
186-195
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). N/A, specified in protocol
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were prespecified.
N/A, specified in protocol
RESULTS
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
207, PRISMA flowchart
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 214-148, Table  2, ESM Table 3 Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Table 1 Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. #4: TS=(cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or shock or (traumatic brain injury or TBI or head trauma) or (stroke or intracranial bleeding or intracranial hemorrhage) or (sepsis or septic shock) or (cardiac surgery or heart surgery or thoracic surgery or thorax surgery) or (cardiac operation or heart operation or thoracic operation or thorax operation) or (acute* surgery or acute* operat*)) #3: TS=((((intensive or critical*) near3 (care or unit or department* or ill*)) or ICU)) #2: TI=((deliri*) or (acute organic psychosyndrome* or acute organic brain syndrome*) or (acute brain dysfunction* or acute brain failure* or acute brain syndrome*) or (postoperati* cognitive dysfunction or post-operati* cognitive dysfunction or postsurg* cognitive dysfunction or post-surg* cognitive dysfunction or postoperati* brain dysfunction or post-operati* brain dysfunction or postsurg* brain dysfunction or post-surg* brain dysfunction or postoperati* psychosis or postoperati* psychosis or postsurg* psychosis or post-surg* psychosis) or (acute psycho-organic syndrome* or acute psychoorganic syndrome* or acute organic psychosyndrome* or acute organic psycho-syndrome*)) #1: TOPIC: ((medication or drug* or agent* or pharmacologic* or antipsychotic* or sedative* or opioid* or benzodiazepin*or aripiprazole or clozapine or haloperidol or olanzapine or quetiapine or risperidone or ziprasidone or dexmedetomidine or clonidine or cholinesterase inhibitor or rivastigmine or donepezil or melatonin* or ketamine))
BIOSIS Previews 1969 to 21.07.17 -263 hits
#6 (#5 AND #2 AND #1) #5 (#4 OR #3) #4 TOPIC: ((cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or shock or (traumatic brain injury or TBI or head trauma) or (stroke or intracranial bleeding or intracranial hemorrhage) or (sepsis or septic shock) or (cardiac surgery or heart surgery or thoracic surgery or thorax surgery) or (cardiac operation or heart operation or thoracic operation or thorax operation) or (acute* surgery or acute* operat*))) #3 TOPIC: (((((intensive or critical*) near3 (care or unit or department* or ill*)) or ICU))) #2 TITLE: (((deliri*) or (acute organic psychosyndrome* or acute organic brain syndrome*) or (acute brain dysfunction* or acute brain failure* or acute brain syndrome*) or (postoperati* cognitive dysfunction or post-operati* cognitive dysfunction or postsurg* cognitive dysfunction or post-surg* cognitive dysfunction or postoperati* brain dysfunction or post-operati* brain dysfunction or postsurg* brain dysfunction or post-surg* brain dysfunction or postoperati* psychosis or post-operati* psychosis or postsurg* psychosis or post-surg* psychosis) or (acute psycho-organic syndrome* or acute psychoorganic syndrome* or acute organic psychosyndrome* or acute organic psycho-syndrome*))) #1 TOPIC: (((medication or drug* or agent* or pharmacologic* or antipsychotic* or sedative* or opioid* or benzodiazepin*or aripiprazole or clozapine or haloperidol or olanzapine or quetiapine or risperidone or ziprasidone or dexmedetomidine or clonidine or cholinesterase inhibitor or rivastigmine or donepezil or melatonin* or ketamine)))
Cinahl 1981 to 21.07.17 -342 hits S23 (S7 AND S10 AND S22) S22 (S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21) S21 AB (cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or shock or (traumatic brain injury or TBI or head trauma) or (stroke or intracranial bleeding or intracranial hemorrhage) or (sepsis or septic shock)or (cardiac surgery or heart surgery or thoracic surgery or thorax surgery) or (cardiac operation or heart operation or thoracic operation or thorax operation) or (acute* surgery or acute* operat*)) S20 AB (((intensive or critical*) and (care or unit or department* or ill*)) or ICU) S19 MJ septic shock S18 MJ sepsis S17 MJ stroke S16 MJ brain injuries S15 MJ Shock S14 MJ Myocardial Infarction S13 MJ Heart Arrest S12 MJ Intensive Care Units S11 MJ critical care S10 (S8 OR S9) S9 AB (((deliri*) or (acute organic psychosyndrome* or acute organic brain syndrome*) or (acute brain dysfunction* or acute brain failure* or acute brain syndrome*) or (postoperati* cognitive dysfunction or post-operati* cognitive dysfunction or postsurg* cognitive dysfunction or post-surg* cognitive dysfunction or postoperati* brain dysfunction or post-operati* brain dysfunction or postsurg* brain dysfunction or post-surg* brain dysfunction or postoperati* psychosis or postoperati* psychosis or postsurg* psychosis or post-surg* psychosis) or (acute psycho-organic syndrome* or acute psychoorganic syndrome* or acute organic psychosyndrome* or acute organic psycho-syndrome*))) S8 MJ Delirium S7 (S1 OR S2 OR S3 OR S4 OR S5 OR S6) S6 AB (medication or drug* or agent* or pharmacologic* or antipsychotic* or sedative* or opioid* or benzodiazepin*or aripiprazole or clozapine or haloperidol or olanzapine or quetiapine or risperidone or ziprasidone or dexmedetomidine or clonidine or cholinesterase inhibitor or rivastigmine or donepezil or melatonin* or ketamine) 
RISK OF BIAS ASSESSMENT OF SYSTEMATIC REVIEWS USING ROBIS
Identifying concerns with the review DOMAIN 1: STUDY ELIGIBILITY CRITERIA Describe the study eligibility criteria, any restrictions on eligibility and whether there was evidence that objectives and eligibility criteria were pre-specified: 1.1 Did the review adhere to pre-defined objectives and eligibility criteria? Y/PY/PN/N/NI 1. 2 Were the eligibility criteria appropriate for the review question? Y/PY/PN/N/NI 1. 3 Were eligibility criteria unambiguous? Y/PY/PN/N/NI 1. 4 Were all restrictions in eligibility criteria based on study characteristics appropriate (e.g. date, sample size, study quality, outcomes measured)? 
CHARACTERISTICS OF SYSTEMATIC REVIEW
Number of trials included Number of participants included ICU population (e.g. medical) Diagnostic criteria of delirium Type of pharmacological agent(s) included Primary and secondary outcomes Results on primary and secondary outcomes Type of meta-analytic and sequential analysis used Authors' conclusion Table 2. Reviews checked against the PRISMA criteria   a   Review identification  #1  #2  #3  #4  #5  #6  #7  #8  #9  #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 #22 #23 #24 #25 
